Pursuant to the provisions of regulation 30 read with regulation 46 of the Listing Regulations, Zydus Lifesciences has informed that it enclosed the Investor Presentation on the audited financial results for the quarter / year ended on March 31, 2026.
The above information is a part of company’s filings submitted to BSE.